Press release
Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Global nonalcoholic steatohepatitis (NASH) treatment market was valued at US$ XX Mn in 2017 and expected to grow at 15.0% Compound Annual Growth Rate (CAGR) over 2018 to 2024
Market Outline: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Nonalcoholic steatohepatitis (NASH) treatment or fatty liver disease develop in the nonalcoholic humans that causes the liver damage which is diagnostically similar to alcoholic hepatitis. Nonalcoholic steatohepatitis may also causes due to glucose intolerance, dyslipidemia, and obesity. NASH is a silent disease with few or no symptoms. Currently a few drugs are available in the market for the treatment of nonalcoholic steatohepatitis treatment.
Market Dynamics: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Increase in the prevalence of metabolic disorders such as diabetes and dyslipidemia are expected to drive the NASH Treatment Market. Moreover, rise in R&D for the innovation of novel therapeutics for NASH disease, promising pipeline products, and change in lifestyle are anticipated to boost the nonalcoholic steatohepatitis treatment market over the forecast period. However, lack of efficient disease diagnosis procedures in early stage, poor understanding of disease pathophysiology, and large medical unmet need may impede the growth of nonalcoholic steatohepatitis market.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
Market Scope: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Global nonalcoholic steatohepatitis (NASH) treatment market is segmented based on the product type and distribution channel
Based on the product type, the market is segmented into the following:
• Simtuzumab and Liraglutide
• GFT 505
• Vitamin E
• Obeticholic Acid (INT-747)
• Pioglitazone
• Others
Based on the distribution channel, the market is segmented into the following:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-c654SbFYO64MsOhu
Regional Analysis: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Geographically, global nonalcoholic steatohepatitis (NASH) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America nonalcoholic steatohepatitis (NASH) treatment market growth driven by increase in the prevalence of NASH disease due to rise in obesity and metabolic disorders (according to American Liver Foundation, approximately 12% of total population has NASH and 3% has advanced liver fibrosis due to NASH) and change in lifestyle are anticipated to fuel the market. Europe nonalcoholic steatohepatitis (NASH) treatment market expected to exhibit lucrative growth due to increase in the R&D for the innovation of newer drugs, rise in prevalence of NASH due to metabolic disorders, and increase in healthcare expenditure. However, a significant growth rate observed in Asia Pacific nonalcoholic steatohepatitis (NASH) treatment market owing to entry of market players into Asia Pacific region, large patient pool, and rise in healthcare expenditure are expected to bolster the market in the region.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-14mlyhjMGhVjZqa3
Competition Assessment: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Some of the players in the global nonalcoholic steatohepatitis (NASH) treatment market include:
• Zydus Cadila (India)
• Genfit SA (France)
• AstraZeneca Plc (UK)
• Gilead Sciences, Inc. (U.S.)
• Conatus Pharmaceuticals, Inc. (U.S.)
• Galmed Pharmaceuticals Ltd (Israel)
• Immuron (Australia)
• Intercept Pharmaceuticals, Inc. (U.S.)
• Tobira Therapeutics, Inc. (U.S.)
• Galectin Therapeutics, Inc. (U.S)
Notable Market Developments: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
In December 2017, Galectin Therapeutics announced the Phase 2b clinical trial results of GR-MD-02 which showed significant results in NASH cirrhosis patients
In January 2018, Genfit started the clinical trials for Children with NASH disease in US with the drug elafibranor
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024 here
News-ID: 1061441 • Views: …
More Releases from Precision Business Insights
Biochar Market Growth Is Attributed To The Increased Production Of Biochar Throu …
According to Precision Business Insights (PBI), the latest report biochar market was valued at USD 243.8 million in 2022, growing at a 12.6% CAGR during the forecast period 2023 to 2029. The rising demand for organic and eco-friendly products drives the biochar market. Utilizing biochar corresponds with organic farming methods, improving market prospects. Furthermore, biochar is a potential material for water treatment and remediation because of its capacity to absorb…
Vapor Recovery Units Market Growth Is Attributed To The Increased Adoption Of Me …
According to Precision Business Insights (PBI), latest report vapor recovery units market was valued at USD 923.7 million in 2022 and is poised to grow at a CAGR of 4.2% during the forecast period 2023 to 2029. The adoption of stringent environmental regulations by governments and international bodies to reduce air pollution and greenhouse gas emissions in various countries drives the demand for the vapor recovery unit's market. Furthermore, the…
Pyrite Market Growth Is Attributed To The Increased Demand In Jewelry Industry
According to Precision Business Insights (PBI), latest report pyrite market is growing at 4.9% CAGR during the forecast period 2023 to 2029. The increased application of pyrite in the manufacturing of sulfuric acid drives the pyrite market. The increase of prices of gold has led to increased demand for imitation jewelry which is anticipated to propel the pyrite market growth. Furthermore, the demand for sulphuric acid in a variety of…
Industrial Boilers Market Growth Is Attributed To The Increased Use In Power Gen …
According to Precision Business Insights (PBI), the latest report industrial boilers market size was valued at USD 15,261.8 million in 2022 and is poised to grow at a 3.1% CAGR during the forecast period 2023 to 2029. The adoption of stringent environmental regulations to maintain emission standards and carbon reduction in several countries drives the industrial boilers market. Furthermore, the advancement in boiler technology, such as better combustion systems, greater…
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report…
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market…
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
